Verastem, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Verastem, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.91M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $10.00M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $2.60M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.05M | Mar 14, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $10.00M | Mar 20, 2025 |
| FY2024 | Dec 31, 2022 | $2.60M | Mar 20, 2025 |
| FY2022 | Dec 31, 2021 | $2.05M | Mar 14, 2023 |
| FY2020 | Dec 31, 2020 | $506.0K | Mar 18, 2021 |
| FY2020 | Sep 30, 2020 | $78.65M | Mar 18, 2021 |
| FY2020 | Jun 30, 2020 | $4.31M | Mar 18, 2021 |
| FY2020 | Mar 31, 2020 | $5.06M | Mar 18, 2021 |
| FY2020 | Dec 31, 2019 | $3.62M | Mar 18, 2021 |
| FY2020 | Sep 30, 2019 | $9.03M | Mar 18, 2021 |
| FY2020 | Jun 30, 2019 | $3.14M | Mar 18, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($209.47M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($130.64M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($87.37M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | ($73.81M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | ($71.20M) | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | ($19.86M) | Mar 18, 2021 |
| FY2020 | Sep 30, 2020 | $13.14M | Mar 18, 2021 |
| FY2020 | Jun 30, 2020 | ($23.01M) | Mar 18, 2021 |
| FY2020 | Mar 31, 2020 | ($37.99M) | Mar 18, 2021 |
| FY2020 | Dec 31, 2019 | ($38.77M) | Mar 18, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($170.13M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($114.96M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($92.08M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | ($72.94M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | ($61.41M) | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | ($16.75M) | Mar 18, 2021 |
| FY2020 | Sep 30, 2020 | $15.02M | Mar 18, 2021 |
| FY2020 | Jun 30, 2020 | ($21.26M) | Mar 18, 2021 |
| FY2020 | Mar 31, 2020 | ($26.36M) | Mar 18, 2021 |
| FY2020 | Dec 31, 2019 | ($33.29M) | Mar 18, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.60M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $81.33M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $61.36M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $50.56M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $39.35M | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | $10.15M | Mar 18, 2021 |
| FY2020 | Sep 30, 2020 | $10.96M | Mar 18, 2021 |
| FY2020 | Jun 30, 2020 | $9.34M | Mar 18, 2021 |
| FY2020 | Mar 31, 2020 | $10.92M | Mar 18, 2021 |
| FY2020 | Dec 31, 2019 | $12.46M | Mar 18, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.15M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $43.62M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $30.73M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $24.98M | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | $24.12M | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | $7.10M | Mar 18, 2021 |
| FY2020 | Sep 30, 2020 | $20.61M | Mar 18, 2021 |
| FY2020 | Jun 30, 2020 | $15.44M | Mar 18, 2021 |
| FY2020 | Mar 31, 2020 | $19.60M | Mar 18, 2021 |
| FY2020 | Dec 31, 2019 | $23.73M | Mar 18, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($137.51M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($104.77M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($86.46M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | ($63.67M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | ($53.50M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($33.51M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | ($138.52M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | ($74.52M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2017 | ($57.31M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | ($29.48M) | Mar 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $28.0K | Mar 4, 2026 |
| FY2023 | Dec 31, 2021 | $196.0K | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $33.0K | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $7.0K | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | $1.51M | Mar 18, 2021 |
| FY2018 | Dec 31, 2016 | $39.0K | Mar 12, 2019 |
| FY2017 | Dec 31, 2015 | $211.0K | Mar 13, 2018 |
| FY2016 | Dec 31, 2014 | $2.43M | Mar 23, 2017 |
| FY2015 | Dec 31, 2013 | $56.0K | Mar 3, 2016 |
| FY2014 | Dec 31, 2012 | $310.0K | Mar 10, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $246.44M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $101.54M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $149.72M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $95.05M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $108.66M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $154.35M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $145.05M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $277.24M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $89.79M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $83.63M | Mar 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $189.25M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $130.43M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $71.19M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $47.66M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $21.10M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $39.08M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $137.87M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $152.94M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $32.11M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $11.33M | Mar 13, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.20M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($28.89M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $57.37M | Mar 4, 2026 |
| FY2025 | Dec 31, 2022 | $47.39M | Mar 4, 2026 |
| FY2024 | Dec 31, 2021 | $87.56M | Mar 20, 2025 |
| FY2023 | Dec 31, 2020 | $115.27M | Mar 14, 2024 |
| FY2022 | Dec 31, 2019 | $7.17M | Mar 14, 2023 |
| FY2021 | Dec 31, 2018 | $124.30M | Mar 28, 2022 |
| FY2020 | Dec 31, 2017 | $57.68M | Mar 18, 2021 |
| FY2019 | Dec 31, 2016 | $72.30M | Mar 11, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.16B) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($955.53M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($824.89M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($737.52M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($663.71M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($592.51M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($524.79M) | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | ($375.58M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($303.14M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($235.32M) | Mar 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $204.99M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $88.82M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $77.91M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $74.93M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $21.25M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $67.78M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $43.51M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | $129.87M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $82.18M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $32.35M | Mar 13, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $40.72M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $40.09M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $24.53M | Mar 14, 2024 |
| FY2017 | Dec 31, 2017 | $15.00B | Mar 13, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | (4) | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 18, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 18, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 18, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Mar 20, 2025 |
| FY2023 | Dec 31, 2021 | (4) | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 18, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 18, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 18, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 77.74M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 44.78M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 25.28M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 16.71M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 185.29M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 170.46M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 80.12M | Mar 18, 2021 |
| FY2019 | Dec 31, 2018 | 73.81M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | 50.80M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 36.99M | Mar 13, 2018 |